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T-Cell Immune Reconstitution in Pediatric Leukemia Patients After Allogeneic
Bone Marrow Transplantation With T-Cell–Depleted or Unmanipulated Grafts:
Evaluation of Overall and Antigen-Speciﬁc T-Cell Repertoires
By Barbara C. Godthelp, Maarten J.D. van Tol, Jaak M. Vossen, and Peter J. van den Elsen
To evaluate the role of T-cell selection in the thymus and/or
periphery in T-cell immune reconstitution after allogeneic
bone marrow transplantation (allo-BMT), we have analyzed
the overall and antigen-specific T-cell repertoires in pediatric
allo-BMT recipients treated for leukemia. We observed a lack
of overall T-cell receptor (TCR) diversity in the repopulating T
cells at 3 months after allo-BMT, as was deduced from
complementarity determining region 3 (CDR3) size distribu-
tion patterns displaying reduced complexity. This was noted
particularly in recipients of a T-cell–depleted (TCD) graft and,
to a lesser extent, also in recipients of unmanipulated grafts.
At 1 year after allo-BMT, normalization was observed of TCR
CDR3 size complexity in almost all recipients. Analysis of the
antigen-specific T-cell repertoire at 1 year after BMT showed
that the T cells responding to tetanus toxoid (TT) differed in
TCR gene segment usage and in amino acid composition of
the CDR3 region when comparing the recipient with the
donor. Moreover, the TT-specific TCR repertoire was found to
be stable within a given allo-BMT recipient, because TT-
specific T cells with completely identical TCRs were found at
3 consecutive years after transplantation. These observa-
tions suggest an important role for T-cell selection processes
in the complete restoration of the T-cell immune repertoire in
children after allo-BMT.
r 1999 by The American Society of Hematology.
A
LLOGENEIC BONE MARROW transplantation (allo-
BMT) is a possibly curative treatment of otherwise
incurable malignant hematologic disorders and severe immuno-
deﬁciency diseases.After allo-BMT, the recipients demonstrate
a varying period of immunoincompetence that can last for up to
several years after transplantation and may cause signiﬁcant
morbidity and mortality.1-4 Moreover, immune reconstitution
can be hampered by the occurrence of acute and chronic
graft-versus-host-disease (GVHD).1,5 Immune reconstitution
after allo-BMT has been studied extensively in adults.1,3,6,7 The
innate immune system, ie, the function of phagocytes, fully
recovers in the ﬁrst weeks to months after BMT, whereas
complete reconstitution of the adaptive immune system, ie, B
and T lymphocytes, takes much longer. As a result, infectious
complications exist for a prolonged time after allo-BMT.8
During normal T-cell development, bone marrow (BM)-
derived T-cell precursors home to the thymus, where they are
subjected to positive and negative selection processes upon
interactions with major histocompatibility complex (MHC)
class I and II molecules expressed on thymic epithelial and
dendritic cells.9-11 These selection processes will ensure a
nonautoreactive peripheral T-cell repertoire that is restricted to
recognizing antigenic peptides in the context of self-MHC.
Within the thymic micro-environment, MHC class II-mediated
interactions result mostly in CD41 T-cell development, whereas
MHC class I-mediated interactions result in CD81 T-cell
development. During T-cell selection in normal individuals,
T-cell receptor (TCR)-B and TCR-Agenes are sequentially and
randomly rearranged from a pool of TCR gene segments,
resulting in a diverse TCR repertoire.12-14 However, this reper-
toire is less diverse than theoretically possible due to nonran-
dom TCRV and TCRJ gene segment usage, nonrandom amino
acid incorporation in the TCR complementarity determining
region 3 (CDR3),15-17 and skewing of certain TCRBV and
TCRAV gene segments towards CD41 or CD81 T-cell sub-
sets.18,19
After the loss of mature T cells, such as occurs after
chemotherapy or after myeloablative conditioning before allo-
BMT, regeneration of the T-cell population can proceed via at
least 2 pathways. First, transfer of graft-derived mature donor T
cells to the periphery followed by antigen-driven expansion.
This process, which represents a thymus-independent pathway
of reconstitution, most likely provides the ﬁrst wave of T cells
after allo-BMT.20-22 These mature T cells with a limited TCR
diversity23 can be maintained in the periphery for up to 10 to 20
years,24 provided that appropriate TCR-peptide/MHC interac-
tions occur.25,26 The second mechanism involves selection of
graft-derived precursor cells in the thymus27-29 and/or possibly
at peripheral selection sites.30,31 The process of thymic T-cell
selection probably accounts for the more durable reconstitution
of the T-cell compartment and potentiates a more diverse TCR
repertoire. Because thymic functions decrease with increasing
age,4,22 this selection mechanism is thought to be the most
effective in young allo-BMT recipients, as is reﬂected by the
delayed recovery of especially CD41 T cells in adult allo-BMT
recipients.3,6,7
At present, it is not precisely known to what extent expansion
of mature graft-derived T cells and thymic selection of precur-
sor T cells contribute to T-cell immune reconstitution after
allo-BMT in children. To address this question, we analyzed in
the present study the overall and antigen-speciﬁc T-cell reper-
toires in well-deﬁned groups of pediatric allo-BMT recipients,
ie, grafted either with BM cells from an HLA-identical sibling
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group, with or without T-cell depletion (TCD) of the graft.
MATERIALS AND METHODS
Patients. Between November 1994 and October 1996, 44 children
with hematologic malignancies were treated with an HLA-identical
allo-BMT at the Department of Pediatrics of the Leiden University
Medical Center (Leiden, The Netherlands). Conditioning of the patients
was performed according to protocols of the Dutch Childhood Leuke-
mia Study Group (DCLSG).All children showed complete engraftment.
Fifteen children died: 11 of relapse of the original disease and 4 of
infection. For the purpose of our study, we selected 3 groups of patients:
(I) myelodysplastic syndrome (MDS) patients treated with aTCD MUD
BM graft; (II) (juvenile) chronic myeloid leukemia [(J)CML] patients
treated with an unmanipulated MUD BM graft; and (III) acute leukemia
patients treated with an unmanipulated HLA-identical sibling BM graft.
The sibling donors were 6 to 25 years old (mean age, 13.1 years),
whereas MUD donors in general were more than 30 years old.TCD ($2
log) of the graft was achieved by albumin gradient centrifugation and
subsequent E-rosette sedimentation.32 Twelve patients who are eligible
for one of the transplantation groups and of which material of the donor
was available were included in our study. These patients received
between 0.75 3 108 and 4.8 3 108 nucleated BM cells (median, 2.4 3
108) per kilogram of body weight (BW). All BMT recipients were
included in a revaccination protocol with diphtheria toxoid (D)-tetanus
toxoid (T)-inactivated polio virus type I, II, and III (IPV) on 10, 14, and
24 weeks after allo-BMT.33 For the purpose of this study, blood was
drawn from the recipients at various time-points after allo-BMT and
from their respective donors. The use of this human material has been
approved by the Committee on Medical Ethics of the Leiden University
Medical Center (Protocol P254/96).
Processing of peripheral blood mononuclear cells (PBMC), ﬂuores-
cence-activated cell sorting (FACS) sorting, and immunophenotypical
analysis. PBMC were isolated from approximately 20 mLheparinized
blood via Ficoll-Isopaque (LUMC Hospital Pharmacy, Leiden, The
Netherlands) density centrifugation. PBMC (2 3 106 to 3 3 106) were
used for FACS sorting to separate CD41 and CD81 T-cell subsets using
ﬂuorescein-conjugated anti-CD4 and R-phycoerythrin-conjugated anti-
CD8 monoclonal antibodies (MoAbs; Dakopatts, Glostrup, Denmark)
and a FACScan (Becton Dickinson, Mountain View, CA). FACS-sorted
subsets (8 3 103 to 3 3 105 cells) were collected in fetal calf serum,
washed twice in phosphate-buffered saline (PBS), and stored at 280°C
until RNA extraction. Immunophenotypical analysis of PBMC was
performed at regular intervals after allo-BMT by ﬂow cytometric
analysis using a FACStar ﬂow cytometer and commercially available
MoAbs in appropriate dilutions: the MoAbs used to discriminate the
various lymphoid subsets were directed against CD3/CD4 or CD3/CD8
for T-cell subsets, CD3/CD16/CD56 for natural killer cells, and CD19
and/or CD20 for B cells. Normalization of the absolute number of cells
in a given lymphocyte (sub)population in the peripheral blood of an
allo-BMT recipient was deﬁned as reaching the ﬁfth percentile of
age-matched reference values.34,36
Generation of antigen-speciﬁc T-cell lines/clones. For the analysis
of the antigen-speciﬁc TCR repertoire, tetanus toxoid (TT)-speciﬁc
T-cell lines were generated as described previously.37 Brieﬂy, 3 to 6 3
106 PBMC were grown in culture medium in the presence of 1.9 limes
ﬂocculationis (lf)/mLTT (RIVM, Bilthoven, The Netherlands).After at
least 2 rounds of TT-stimulation and subsequent TT-speciﬁcity testing
in a 3H-thymidine incorporation assay, T-cell clones were generated
from some of these lines by limiting dilution.38 The T-cell lines and
clones that, after repeated testing, had a stimulation index (SI) greater
than 3, with more than 5 3 103 counts per minute (cpm) in the case of
T-cell lines or more than 1 3 103 cpm in the case of T-cell clones, were
considered to be TT-speciﬁc (SI5 3H incorporation of T1APC1TT/3H
incorporation T1APC only). Epstein-Barr virus (EBV)-transformed
B-cell lines of recipients and their respective donors (MUD/siblings)
were used as antigen-presenting cells (APC) in these tests. Blocking of
the proliferative response was analyzed as described previously37 using
MoAbs directed against MHC class I (W6/32), MHC class II (PdV5.2),
CD4 (RIV6), and HLA-DR (B8.11.2), which remained present during
the entire assay.
RNA extraction, cDNA synthesis, and polymerase chain reaction
(PCR) ampliﬁcation. Total RNA was extracted from FACS-sorted
CD41 and CD81 T-cell subsets and from TT-speciﬁc T-cell clones (8 3
103 to 1 3 106 cells). The RNA was converted into cDNA using
oligo-dT (Promega, Madison, WI). The cDNA was subjected to PCR
ampliﬁcation for the determination of TCR gene segment usage. PCR
ampliﬁcation and TCR-primers were as described previously.19,37
Spectratyping and method validation. The distribution of TCR
CDR3 sizes was analyzed by PCR.39 PCR reactions were performed
with 58 TCRBV family speciﬁc primers (TCRBV1-23) and a 38 generic
TCRBC internal primer labeled with [g-32P]ATP as described previ-
ously.37,39 To avoid a hampered size distribution due to very small
numbers of T cells in the starting material, we used cDNAfrom at least
8 3 103 sorted cells for each spectratype, because we and others40,41
have determined that approximately 2 3 103 cells is the lowest number
at which a near normal distribution of TCR CDR3 sizes with 8 to 10
distinct bands can be observed in the majority of theTCRBVfamilies in
CD41 and CD81 T-cell subsets (Fig 1). Furthermore, identical TCR
CDR3 size distribution patterns were obtained after repeated spectra-
type PCR (results not shown).
PCR fragment puriﬁcation and DNA sequencing. The desired
TCRBV PCR fragments were puriﬁed by electrophoresis in a 1% low
melting point agarose gel and subsequent use of Wizard columns
(Promega). The Wizard-puriﬁed fragment was used for direct sequenc-
ing42 using the T7 sequencing Kit (Pharmacia LKB, Uppsala, Sweden)
with 5 to 10 pmol of TCRBC internal primer, approximately 0.25 pmol
PCR fragment, and [a-33P]ATP (0.5 µCi; Dupont NEN, Boston, MA).
DNA sequences were compared with TCR sequences contained in the
GenBank using the PCGENE Computer Software Program (Release
6.85; Intelligenetics Inc, PaloAlto, CA).
Sequencing/spectratyping oligonucleotide primer. The primer used
for sequencing of the TCR of TT-speciﬁc T-cell clones and for the
spectratype analysis was TCRBC internal (58 TGT GGG AGA TCT
CTG CTT CTG 38).
TCR CDR3-speciﬁc oligonucleotide hybridization. For the analysis
of the persistence of TCR clonotypes, TCRBV9 PCR products were
generated fromTT-speciﬁcT-cell lines and clones,37 size-fractionated in
a 1% agarose gel, and transferred to nylon membranes (HybondN1;
Amersham, Little Chalfont, UK) in 203 SSPE for 17 hours. After
blotting, ﬁlters were incubated in 0.4 N NaOH for 20 minutes and
washed in 53 SSPE for 5 minutes at room temperature. Filters were
prehybridized and hybridized at 60°C in 53 SSPE, 0.1% bovine serum
albumin (BSA), 0.1% Ficoll, 0.1% polyvinylpyrolidone, and 0.5%
sodium dodecyl sulfate (SDS). The oligonucleotide probe speciﬁc for
the TCR CDR3 region of the UPN 285-derived sequence TCRBV9S1
PTGSG was composed of 58 CAGTGCCGCTCCCTGTAGGGCTGC
38 and was end-labeled with [g-32P]ATP as described above. After the
hybridization in a hybridization oven (Appligene Inc, Pleasanton, CA)
for 17 hours at 60°C, the ﬁlters were washed once in 63 SSPE, 0.1%
SDS, pH 7.5, for 15 minutes at 60°C and once in 63 SSPE, 0.1% SDS,
pH 7.5, for 15 minutes at 78°C (Tm of the oligo). After washing, the
ﬁlters were exposed to x-ray ﬁlms at 280°C for 2 to 4 hours.
RESULTS
Transplant outcome. Successful engraftment was observed
in all analyzed children. In the total group of analyzed children
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recipients who received a TCD-BM graft (I), 2 of 3 children
(67%) survived, and in the groups who received unmanipulated
BM grafts (II1III), 7 of 9 children (78%) survived. Causes of
death were relapse of the original disease in 2 children and
EBV-induced B-cell lymphoproliferative disease (BLPD) in 1
child. Acute GVHD grade I was observed in 5 children and
chronic GVHD developed in 4 children (3 limited and 1
extensive). Almost all survivors are alive with a follow-up of 3
to 4 years after allo-BMT and have a Karnofsky score of 100%,
whereas UPN 298, who suffers from extensive chronic GVHD,
including the liver, has a Karnofsky score of 80%. The
transplant-related variables and the allo-BMT outcome of all
analyzed patients are summarized in Table 1.
Immunological reconstitution: recovery of the main lympho-
cyte subsets. Absolute lymphocyte counts below the ﬁfth
percentile (p5) of age-matched reference values34,35 were ob-
served in 10 of 12 children at 3 months after allo-BMT, as
shown in Table 2. The absolute numbers of CD31 T cells at this
time-point were below p5 values in 8 of 12 recipients. In 4 of 12
allo-BMT recipients, all from the unmanipulated graft groups,
normal numbers of CD31 T cells were detected. The absolute
number of CD41 T cells was low in almost all recipients at 3
months after allo-BMT (11 of 12 patients), irrespective of the
nature of the graft (TCD or unmanipulated). In contrast, CD81
T-cell numbers were either normal (6 of 12 patients), increased
(2 of 12 patients), or decreased (4 of 12 patients) at this
time-point.TheabsolutenumberofNKcells(CD32CD161561)
was normal at 3 months post-BMT in the majority of the
recipients (11 of 12), whereas the absolute number of B cells
(CD201) was decreased in the majority of the analyzed
recipients (8 of 12). Similar analyses at 1 year after allo-BMT
showed normalization of lymphocyte numbers in the majority
of the patients (Table 2). The absolute number of CD31 cells
increased in 7 of 9 patients when comparing the 2 time-points.
However, CD31 T-cell numbers remained below the p5 of
reference values in 3 of 9 patients at 1 year after BMT. Similar
observations were made for CD41 T cells. CD81 T cells
either reached normal values (4 of 9 patients) or were slightly
increased (4 of 9 patients) at 1 year after allo-BMT. The number
of NK cells (CD32CD161CD561) cells reached normal levels
in the majority of the patients (7 of 9 patients), whereas B-cell
numbers (CD201) were either normal (5 of 9 patients) or
slightly increased (4 of 9 patients) at this time-point.
CD45RA and CD45RO expression proﬁles on CD41 and
CD81 T-cell subsets. At approximately 3 months after allo-
BMT,theabsolutenumberofCD41TcellsexpressingCD45RA
was low in all 11 children investigated (mean, 0.037 3 103
cells/µL), whereas the absolute number of CD81 T cells
expressing this marker was much higher (mean, 0.29 3 103
cells/µL; Table 3). The absolute number of CD41 T cells
expressing the memory marker CD45RO (mean, 0.21 3 103
cells/µL) was signiﬁcantly higher than the number of
CD41CD45RA1 T cells. Within the CD81 T-cell subset,
expression of CD45RAand CD45RO was variable: the absolute
number of CD81CD45RO1 T cells was higher than that of
CD81CD45RA1 T cells in 5 of 11 patients, lower in 3 of 11
patients,andinthesamerangein3of11children.Similaranalyses
at 12 months after allo-BMT showed an increase in the number
of CD41CD45RA1 T cells in 9 of 9 recipients, but the counts
were still below the p5 of age-matched reference values in the
majority of the patients. Moreover, an increase in the absolute
number of CD81CD45RA1 T cells was observed in 8 of 9
recipients.Absolute numbers of memory (CD45RO1) cells also
increased in CD41 as well as in CD81 T-cell subsets, in 7 of 9
and 4 of 9 recipients, respectively, showing expansion of
memory-type T cells within the ﬁrst year after transplantation.
TCR CDR3 size proﬁle analysis. The overall TCR reper-
toire diversity was investigated by evaluation of theTCR CDR3
size distribution patterns. Spectratype analysis of TCD-graft
recipients (group I) at 3 months after allo-BMT demonstrated
TCR CDR3 size distribution patterns that were deviated from a
Gaussian distribution in both T-cell subsets in the majority of
the TCRBV families (Table 4) when compared with their
donorsorage-matchedcontrolswhodisplayedGaussiandistrib-
uted spectratypes (results not shown). It should be noted that the
Fig 1. Method validation of TCR CDR3 size distribution analysis. A cDNA sample of sorted CD41 and CD81 T cells from a healthy bone marrow
donor was serially diluted to determine the number of cells at which a near normal distribution of TCR CDR3 sizes (8 to 10 bands) in the majority
of the TCRBV families could be obtained after a TCRBV-specific spectratype PCR. Shown are the size distributions for undiluted cDNA and a 5-,
10-, and 20-fold dilution representing 30 3 103, 6.0 3 103, 3.0 3 103, and 1.5 3 103 cells in each spectratype for TCRBV1, TCRBV2, and TCRBV3 in
CD41 and CD81 T-cell subsets.
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BW of the recipient) mature T cells after the depletion
procedure as estimated by FACS analysis (results not shown).
At 1 year post-BMT, a more or less normal distribution of TCR
CDR3 sizes was observed in the majority of the TCRBV
families in these TCD graft recipients when a similar number of
cells was used as for the early analysis.Analyses of TCR CDR3
size distribution patterns in unmanipulated-graft recipients
(group II1III) showed less heterogenous patterns at 3 months
after transplantation, whereas a Gaussian distribution of TCR
CDR3 sizes could be observed at 1 year after allo-BMT. When
comparing the spectratypes at 3 months after transplantation in
the 3 transplantation groups, a more diverseTCR repertoire was
observed in the unmanipulated graft groups (3 of 4 children), as
summarized in Table 4, irrespective of the number of cells used
for the analyses. For example, the deviated TCR CDR3 size
distribution pattern of UPN 272 at 3 months after BMT, the less
heterogenous size distribution (3 months post-BMT) of UPN
301, and the Gaussian size distribution (1 year post-BMT) of
UPN 301 were all generated with 8 3 103 cells. Representative
examples of TCR CDR3 size distribution patterns are shown in
Fig 2.
To study the kinetics of the TCR repertoire development
more closely, we have analyzed TCR CDR3 size distribution
patterns of UPN 272 (group I) at 5 time-points after allo-BMT
in CD41 and CD81 T-cell subsets (Fig 3). This showed the
presence of dominantT-cell clonotypes early after allo-BMT, ie,
at 6 to 10 weeks in almost all analyzed TCRBV families in both
T-cell subsets. These early T-cell clonotypes most probably
represent donor memory T cells contained in the BM graft. At
later time-points, the TCR diversity increased, but the dominant
clonotypes remained present. However, the TCRBV9,
TCRBV20, and TCRBV22 spectratypes remained less heterog-
enous in the CD81 T-cell subset at later time-points (Fig 3).
TT-speciﬁc T-cell immune response after allo-BMT. To
follow the restoration of the proliferative response against the
recall antigen TT in time, PBMC obtained at 6, 10, 14, 32, and
52 weeks after allo-BMT were stimulated with TT. The
responding T cells were tested for their TT-speciﬁcity in 3H
thymidine incorporation assays. These analyses showed the
lack of a signiﬁcant proliferative response to TT in T-cell lines
of all 6 recipients generated at the early time points (4 to 14
weeks) after allo-BMT (Table 5), whereas the response of these
T-cell lines to phytohemagglutinin (PHA) was in normal range
Table 1. Clinical Characteristics and Allo-BMT Outcome
Patient Diagnosis* Conditioning†
GVHD‡
GVHD
Prophylaxis§ IVIG\ Infections¶ Current Status Acute Chronic
I#
UPN 272 MDS(RAEBt) AraC/Cy/TBI12 gr I L MTX/Cam 1 H parainfluenzae,
VZV
Relapse, alive
in remission
UPN 273 MDS(RAEB) AraC/Cy/TBI12 No — MTX/Cam/CsA 2 EBV Died, infection
(BLPD)
UPN 279 MDS(RAEBt) AraC/Cy/TBI12 No No MTX/Cam 1 S epidermidis Alive and well
II
UPN 298 JCML Cy/TBI7.5 gr I E MTX/CsA/Cam 1 CMV, VZV Alive
UPN 301 CML(Ph1, CP) AraC/Bu/Cy No No MTX/CsA/Cam 1 — Alive and well
UPN 329 JCML Bu/Cy200 gr I L MTX/CsA 2 CMV, RSV Died, relapse
III
UPN 274 ALL II VP16/Cy/TBI7.5 No No MTX/CsA 1 P aeruginosa, A
fumigatus
Died, relapse
UPN 275 AML II AraC/Cy/TBI8 No No MTX/CsA 2 — Alive and well
UPN 276 AML I AraC/Cy/TBI12 No No MTX/CsA 1 HSV, VZV Alive and well
UPN 285 ALL II VP16/Cy/TBI7.5 gr I No MTX/CsA 1 VZV Alive and well
UPN 291 ALL II VP16/Cy/TBI12 No No MTX/CsA 1 — Alive and well
UPN 296 ALL II VP16/Cy/TBI12 gr I L MTX 1 S epidermidis, VZV Alive and well
*Diagnosis: MDS(RAEB)/(RAEBt), myelodysplastic syndrome with refractory anemia and excess of blasts; t, in transformation; (J)CML,
(juvenile) chronic myeloid leukemia; Ph1, with presence of Philadelphia chromosome; CP, in chronic phase; ALL, acute lymphoid leukemia; AML,
acute myeloid leukemia in first (I) or second (II) complete remission.
†Conditioning: AraC, total dose of 4 g/m2 cytosine arabinoside; Cy, total dose of 120 mg/kg body weight (BW) cyclophosphamide, with the
exception of UPN 329 who received 200 mg/kg BW; Bu, total dose of 20 mg/kg BW busulfan; VP16, total dose of 700 mg/m2 etoposide; TBI, total
body irradiation either a single dose of 7.5/8 Gy or 2 3 6G y .
‡Acute GVHD with grade (gr) I-IV; chronic GVHD is either limited (L) or extensive (E).
§GVHD prophylaxis consisted of a total dose of methotrexate (MTX) at 10 mg/m2 33 accompanied by Campath (Cam) at 0.2 mg/kg BW 34 and/or
CsA at 2 mg/kg BW/d intravenously (day 25t o130 followed by 6 mg/kg BW/d/os through day 1180) and tapered off until discontinuation at day
1280; or MTX at 10 mg/m2 34 followed by 10 mg/m2/wk until day 1100 (UPN 296).
\Intravenous Ig, administration 1 to 3 months after allo-BMT.
¶Severe infections, ie, bacteraemia, septicaemia, pneumonia (A Fumigatus), and virus reactivations/infections, occurring within the first year
after BMT (onset of all infections was from 5 to 134 days post-BMT). VZV, varicella-zoster virus; EBV, Epstein-Barr virus; CMV, cytomegalovirus
(pp65-antigenemia, pre-emptively treated with gancyclovir); RSV, respiratory syncytial virus; HSV, herpes simplex virus.
#Transplantation groups: I, TCD BM graft from MUD; II, unmanipulated BM graft from MUD; III, unmanipulated BM graft from HLA-identical
sibling donor.
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Patient
Age at
BMT
(yrs)
No. of
Lymphocytes*
No. of
CD31
No. of
CD41
No. of
CD81
No. of
CD161/561
(CD32)
No. of
CD201
3 1 231 231 231 231 231 2
I†
UPN 272 11 1.05 1.12 0.89 0.71 0.09 0.15 0.81 0.55 0.03 0.10 0.12 0.29
UPN 273‡ 12 0.50 § 0.20 — 0.13 — 0.11 — 0.30 — 0.03 —
UPN 279 10 1.05 2.76 0.15 1.35 0.05 0.97 0.13 0.41 0.38 0.25 0.39 1.0
II
UPN 298 7 0.68 5.25 0.51 4.25 0.03 0.79 0.48 3.30 0.20 0.47 0.007 0.21
UPN 301 2 1.88 3.07 1.39 2.18 0.76 1.35 0.76 0.68 0.47 0.06 0.17 0.65
UPN 329 2 1.34 § 0.48 — 0.20 — 0.29 — 0.34 — 0.25 —
III
UPN 274 6 0.62 § 0.56 — 0.09 — 0.47 — 0.11 — 0.006 —
UPN 275 11 1.87 2.96 1.46 2.16 0.19 0.59 1.25 1.6 0.32 0.47 0.08 0.62
UPN 276 14 1.36 2.93 1.09 2.08 0.39 0.85 0.71 1.29 0.20 0.41 0.09 0.70
UPN 285 10 1.03 1.96 0.73 0.80 0.22 0.53 0.58 0.55 0.27 0.31 0.02 0.80
UPN 291 7 1.72 3.50 1.31 2.21 0.24 0.98 1.07 1.23 0.21 0.25 0.21 0.95
UPN 296 15 0.83 0.43 0.37 0.23 0.12 0.15 0.21 0.09 0.18 0.09 0.22 0.23
Reference\ 2-4 3.7 (2.3-5.4) 2.1 (1.2-3.7) 1.3 (0.7-2.4) 0.7 (0.4-1.1) 0.5 (0.2-0.7) 0.8 (0.4-1.4)
5-9 2.6 (1.7-3.5) 1.8 (1.0-2.6) 1.0 (0.6-1.5) 0.6 (0.3-1.0) 0.2 (0.1-0.5) 0.3 (0.2-0.7)
10-14 2.4 (1.6-3.1) 1.6 (0.9-2.4) 0.9 (0.6-1.6) 0.5 (0.2-0.9) 0.3 (0.1-0.5) 0.3 (0.1-0.6)
15-70 1.9 (1.3-3.0) 1.3 (0.8-1.9) 0.8 (0.5-1.2) 0.4 (0.3-0.8) 0.3 (0.1-0.6) 0.3 (0.1-0.6)
*Absolute numbers: 3103 cells/µL peripheral blood.
†Transplantation groups as mentioned in Table 1.
‡Analysis at 68 days post-BMT; other time-points were not available.
§Recipient died before second analysis at 1 year after transplantation (UPN 273, UPN 329, and UPN 274).
\Age-matched reference values according to Comans-Bitter et al34; values are the median, with ranges from 5 to 95 percentiles in parentheses.
Table 3. Absolute Numbers of CD45RA1 and CD45RO1 T Cells in CD41 and CD81 T-Cell Subsets at 3 and 12 Months After Transplantation
Recipient
Age at
BMT (yrs)
No. of CD4
CD45RA1*
No. of CD4
CD45RO1
No. of CD8
CD45RA1
No. of CD8
CD45RO1
3 1 2 31 231 231 2
I†
UPN 272 11 0.004 0.03 0.13 0.13 0.14 0.29 0.68 0.42
UPN 273 12 ND ‡ ND — ND — ND —
UPN 279 10 0.007 0.59 0.05 0.38 0.08 0.31 0.05 0.13
II
UPN 298 7 0.004 0.08 0.03 0.73 0.18 1.60 0.37 2.40
UPN 301 2 0.13 1.08 0.72 0.24 0.23 0.62 0.64 0.05
UPN 329 2 0.05 ‡ 0.18 — 0.15 — 0.22 —
III
UPN 274 6 0.01 ‡ 0.08 — 0.23 — 0.21 —
UPN 275 11 0.03 0.19 0.14 0.42 0.7 1.14 0.51 0.80
UPN 276 14 0.03 0.28 0.37 0.65 0.55 1.11 0.27 0.46
UPN 285 10 0.04 0.10 0.21 0.44 0.31 0.38 0.30 0.19
UPN 291 7 0.06 0.46 0.20 0.51 0.31 0.50 0.92 0.76
UPN 296 15 0.01 0.04 0.10 0.13 0.12 0.07 0.11 0.02
Reference§ 1-6 1.14 (0.66-1.39) 0.6 (0.4-1.5) 1.0 (0.6-1.3) 0.1 (0.1-0.5)
7-17 0.49 (0.39-0.74)
18-70 0.32 (0.22-0.54) 0.3 (0.1-0.8) 0.4 (0.1-0.8) 0.2 (0.2-0.4)
The number of CD45RA1 and CD45RO1 cells within the CD41 and CD81 T-cell subsets was determined after staining with anti-CD45RA and
anti-CD45RO MoAbs; RA1RO1 double-positive T cells were calculated as well.
Abbreviation: ND, not determined.
*Absolute numbers of cells: 3103/µL peripheral blood.
†Transplantation groups as mentioned in Table 1.
‡Patient died before second analysis.
§Age-matched CD41CD45RA1 reference values,35 with ranges from 25 to 75 percentiles in parentheses. Reference values for CD41CD45RO1 T
cells and for CD45RA1- and CD45RO1-CD81 T cells were only available for children of 1 year old and for adults; values are the median, followed by
minimal and maximal absolute counts in parentheses.36
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T-cell line of UPN 275 generated at 14 weeks after allo-BMT
showed a very weak proliferative response to TT (SI, ,5),
albeit with counts less than 10 3 103 cpm. Furthermore,
T-cell–dependent B-cell reponses to TT were also lacking at
these time-points in all analyzed recipients, as shown by the
level of TT-speciﬁc Igs that did not increase after repeated
DTP-vaccination (results not shown). Of note was the observa-
tion that, after 3 DTP-vaccinations, the TT-speciﬁc B-cell
responses were completely absent in 5 of 6 analyzed recipients,
with the only exception being UPN 275, who showed a
moderate increase in TT-speciﬁc Igs (both IgG1 and IgG3) after
the third vaccination (results not shown). T-cell lines generated
at 32 weeks after transplantation were found to beTT-speciﬁc in
4 of 5 analyzed recipients, as were T-cell lines generated at 52
weeks after allo-BMT (Table 5 and Fig 4). The lack of a
proliferative response to TT in UPN 301 corresponded with
standard PBMC culture assay results (results not shown). A
similar analysis of T-cell lines of the respective BM donors (Fig
4) showed normal proliferative responses to PHA(SI, 26 to 59)
in all 5 analyzed donors, whereas only 3 of 5 donors responded
to TT (SI, 1.3 to 43), which is probably related to the
TT-vaccination status of these donors.
Because almost all allo-BMT recipients have received cyclo-
sporin A (CsA) as GVHD prophylaxis until 40 weeks after
transplantation (Table 1), we used the T-cell lines generated at
52 weeks after allo-BMT for the analysis of T cells at the clonal
level. T-cell clones were generated from TT-speciﬁc T-cell lines
derived from UPN 275 and UPN 285 of the unmanipulated graft
group (group III) and from their BM donors by limiting
dilution. Because both UPN 275 and UPN 285 were trans-
planted with a sex-mismatched graft, chimerism patterns could
be determined via X-Y ﬂuorescence in situ hybridization
(FISH),43 which showed that the T cells in both recipients were
completely of donor origin (results not shown). The TT-speciﬁc
proliferation of these donor-type T cells was found to be
CD4-mediated and HLA-DR–restricted, because the addition of
anti-CD4 MoAb, anti-MHC class II MoAb, or anti-HLA DR
MoAb inhibited this proliferative response with 77% to 91%,
whereas after the addition of anti-MHC class I MoAbs, only a
nonspeciﬁc inhibition of 29% to 40% could be observed (Fig 5).
DNA-sequence analysis of TT-speciﬁc T-cell clones after
allo-BMT and detection of stable TCR CDR3 clonotypes in
T-cell lines. When comparing TCR sequences of TT-speciﬁc
T-cell clones from allo-BMT recipients (group III) with those
from their donors, a striking dissimilarity was found in the
usage of TCRBV and TCRBJ gene segments and in the amino
acid composition of the CDR3 region (Table 6). This suggests
that the T cells responding to TT in the recipients at 52 weeks
after allo-BMT are composed of newly selected precursor T
cells that are educated in the recipient. The number of different
TCR sequences was low in the donors (3 to 5) and high in the
recipients (11 to 13), which may reﬂect a relative naive anti-TT
immune response in the patient and a memory-type immune
response in the donor. In all analyzed individuals, one particular
TCR sequence was found multiple times, showing the dominant
character of these clones in the TT-speciﬁc T-cell lines (Table 6,
in italics).
Longitudinal analysis of the T cells responding to TT showed
stability of the TCR repertoire within 1 allo-BMT recipient
(UPN 285; Fig 6). The presence of T cells expressing the
TCRBV9S1 (PTGSG) TCR (Table 5) could be demonstrated in
TT-speciﬁcT-cell lines and/or clones of UPN 285 generated at 3
consecutive years after allo-BMT (Fig 6); similar results were
obtained with the TCRBV1S1 (GLG) and TCRBV5S1
(YRGLAQG) TCRs (results not shown). Moreover, the pres-
ence of T cells with the donor-type TCRBV5S6 TCR (GGLAG
I) could not be demonstrated in the UPN 285-derived T-cell
lines and clones at the 3 analyzed time-points (results not
shown), arguing against a major role for peripheral expansion of
graft-derived memory T cells in this patient.
DISCUSSION
In the present study, we analyzed the T-cell immune recovery
in well-deﬁned groups of pediatric allo-BMT recipients to
investigate the relative contribution of expansion of transferred
mature donor T cells and of thymic selection of donor precursor
T cells in this process. Immunophenotypic analysis showed that
the pediatric recipients analyzed in this study have extremely
low numbers of CD41 and low to normal numbers of CD81 T
cells (Table 2) at 3 months post-BMT, which is in line with
previously published data from TCD BMT46-48 as well as from
full graft BMT in children.48-51 At this time-point, the absolute
number of CD41 T cells expressing the CD45RA1 naive
marker was low, whereas the number of CD81 T cells express-
ing this marker was much higher (Table 3).41,49-51This relatively
quick recovery of CD81 T cells expressing CD45RA may be
due to selection via an alternative regeneration pathway as
Table 4. TCR CDR3 Size Distribution Analysis of Allo-BMT Recipients
at 3 and 12 Months Post-BMT in CD41 and CD81 T-Cell Subsets
Recipient/
Sample
3 mo Post-BMT 12 mo Post-BMT
4/8 Ratio* Spectratype† 4/8 Ratio Spectratype
I
UPN 272 0.22 D/LH 0.28 G
UPN 279 2.60 D/LH‡ 2.40 G
II
UPN 298 0.21 D/LH 0.23 G/LH
UPN 301 1.7 LH/G 1.5 G
III
UPN 275 0.10 LH/G 0.32 G
UPN 285 2.10 LH/G 3.90 G
*CD4/CD8 T-cell ratio was determined after staining PBMC with
appropriate MoAbs and FACS sorting; only true CD31CD81high T cells
were calculated.
†Spectratype classification: G 5 Gaussian, ie, normal distribution of
TCR CDR3 sizes with 7 to 12 bands in the majority of the TCRBV
families; LH, less heterogenous size distribution, ie, reduced number
of bands and/or with different band intensity (3 to 5 dominant bands, 1
to 3 accompanying bands); D, deviated size distribution pattern,
severely reduced number of bands (1 to 4 bands) with different band
intensity; D/LH, deviated in the majority of the TCRBV families and a
less heterogenous distribution in less than 30% of the TCRBV families
in CD41 as well as CD81 T-cell subsets; LH/G, less heterogenous
distribution in the majority of the TCRBV families and a Gaussian
distribution in less than 30% of the TCRBV families in both T-cell
subsets.
‡The deviated TCR size distribution patterns were more frequently
found in CD81 than in CD41 T cells.
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Fig 2. Representative examples of deviated and normal TCR CDR3 size distributions. (A) Analysis of CDR3 size distribution patterns in UPN
272 at 3 months after allo-BMT in CD41 and CD81 T-cell subsets as an example of a deviated/less heterogenous distribution of TCR CDR3 sizes. (B)
Similar analysis in UPN 301 at 3 months after allo-BMT in CD41 and CD81 T-cell subsets as an example of a less heterogenous/Gaussian
distribution of TCR CDR3 sizes. (C) UPN 301 at 1 year after allo-BMT in CD41 and CD81 T-cell subsets as an example of a Gaussian distribution of
TCR CDR3 sizes. Lanes indicate from left to right TCRBV families (1 through 23).
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BMT recipient50 or, less likely, due to conversion of CD45RO1
cells to CD45RA1 end-stage effector T cells. These
CD81CD45RA1 end-stage effector cells with a LFA1high and/or
CD29high phenotype have been found in adults and also in
children, albeit to a much lesser extent.52,53 At 1 year after
allo-BMT, naive CD41CD45RA1 T-cell numbers increased but
remained below age-matched reference values in the majority
of the analyzed recipients (Table 3). This ﬁnding is in contrast
with the quick recovery of naive CD41 T cells that was
observed in children after convential chemotherapy.54 It can be
argued that the preparative regimen including total body
irradiation (TBI), which was administered to our patients before
allo-BMT and the CsA, which was administered as GVHD
prophylaxis,55,56 may have damaged the thymus more severely
and, therefore, may have delayed the recovery of naive CD41 T
cells. Of note was the observation that the memory-type
(CD45RO1) T cells increased as well, in particular in the CD41
T-cell subset (Table 3), suggesting that naive cells may have
become memory cells after proper activation or that mature
graft-derived memory cells may have expanded in these allo-
BMT recipients.
Analysis of the TCR diversity at 3 months post-BMT showed
that pediatric recipients of TCD grafts and, to a lesser extent,
those receiving unmanipulated grafts display deviated TCR
CDR3 size distribution patterns in the majority of TCRBV
families (Table 4 and Fig 2). The skewed size proﬁles were not
due to small numbers of cells in the spectratype analyses,
because sufficient T cells were used to ensure a normal
distribution (Fig 1).These observations are in concordance with
data from adult BMT57 but are in contrast with other studies
only showing limitedTCR diversity in recipients of aTCD graft
but not in recipients of unmanipulated grafts.23,39,58,59 Differ-
ences in cell populations used, ie, PBMC versus sorted CD41
and CD81 T-cell subsets, for the size distribution analysis and
the time of analysis after allo-BMT may account for these
differences. The TCR CDR3 size complexity increased to
normal levels in the majority of the recipients within the ﬁrst
year after allo-BMT, irrespective of the nature of the graft and
irrespective of the CD4/CD8 ratio (Table 4). Furthermore, we
were able to show that the few dominant TCR clonotypes that
were present early after transplantation persisted at later time-
points (Fig 3). These dominant TCR clonotypes most likely
represent mature graft-derived T cells, because all grafts, even
the TCD ones, contained substantial numbers of T cells.
Whether these clones persist and/or expand after allo-BMT due
to acute GVHD,57,60 infections,61,62 or other antigenic exposure
is a matter of debate. However, there is no correlation with acute
GVHD in our study, because only mild GVHD (grade I) was
observed. Only UPN 298, who suffered from acute GVHD
grade I and extensive chronic GVHD, displayed a skewed TCR
CDR3 size distribution pattern even at 1 year after allo-BMT
(Table 4). Although TCR repertoire diversity increased in the
majority of the young allo-BMT recipients within the ﬁrst year
after allo-BMT, which is suggestive for a role of precursor
T-cell selection most probably in the thymus, some TCRBV
families remained less heterogenous in the CD81 T-cell subset
(Fig 3), which could be related to the age of the matched
unrelated donor.63,64
TT-speciﬁc T-cell proliferative responses were found to be
absent at the early time points after allo-BMT in all analyzed
recipients (Table 5), which may correlate with the low number
of CD41 T cells (Table 2), most probably resulting in a low
number of T-cell precursors directed against TT. Alternatively,
the GVHD prophylaxis with CsAthat was administered until 40
weeks after transplantation may underlie this lack of antigen-
speciﬁc proliferative T-cell responses. Besides a direct effect on
Fig 3. Presence and persistence of dominant TCR clonotypes after
allo-BMT. Longitudinal analysis of TCR CDR3 size distribution pat-
terns in UPN 272 (transplantation group I) at 6, 10, 14, 28, and 52
weeks after the TCD allo-BMT. Shown are spectratypes of TCRBV3,
TCRBV5, TCRBV9, and TCRBV19 in the CD41 as well as in the CD81
T-cell subsets
Table 5. TT-Specific Proliferative Responses of T-Cell Lines
at Several Time-Points After Allo-BMT
Recipient
TT Proliferation (SI 1 SD),* Time-Point of Analysis (wks)
t 5 6 wks t 5 10 wks t 5 14 wks t 5 32 wks t 5 52 wks
UPN 272 0.6 6 0.3 1.0 6 0.3 1.0 6 0.3 11† 6 32 6 6 6
UPN 279 ND 1.3 6 0.4 2.4 6 0.8 23 6 73 6 6 12
UPN 298 1.1 6 0.3 1.1 6 0.3 1.5 6 0.5 ND ND
UPN 301 1.1 6 0.3 ND 1.1 6 0.3 1.1 6 0.3 2.1 6 1
UPN 275 0.8 6 0.2 1.7 6 0.6 5.7 6 2.9 21 6 61 6 6 4
UPN 285 1.1 6 0.3 1.6 6 0.5 2.0 6 0.7 17 6 62 7 6 8
Abbreviation: ND, not determined.
*SI were calculated as SI 5 3H incorporation of T cells 1 APC 1
antigen/3H incorporation of T cells and APC only; depicted is the mean
SI of 3 experiments 6 standard deviation (SD). The background values
varied between 0.5 3 103 and 4.0 3 103 cpm and TT values varied
between 0.7 3 103 and 84 3 103 cpm.
†TT-stimulated T-cell lines were considered to be TT-specific when
SI were 3 or greater (and cpm .5 3 103); these SI values are
underlined.
T-CELL IMMUNE RECONSTITUTION AFTER ALLO-BMT 4365
For personal use only. on November 7, 2014.  by guest    www.bloodjournal.org From the thymic microenvironment inﬂuencing T-cell selection, CsA
blocks the transcription of the IL-2 gene via interference with
promoter occupancy in naive as well as in activated T cells and
may therefore inhibit the activation of newly selected precursor
cells with TT as well as the reactivation of graft-derived
TT-speciﬁc memory T cells.65,66
All further molecular analyses were therefore performed with
the T-cell lines generated at 52 weeks after allo-BMT, ie, after
discontinuation of the CsA treatment. These TT-speciﬁc T-cell
clones were all CD41 and recognized TT with HLA-DR as
restriction element (Fig 5). Longitudinal analysis of the T cells
responding to TT showed that at least part of the TCR repertoire
is stable within a given allo-BMT recipient (Fig 6), as was
reported before for responses against HIV 1 glycoprotein 41,67
the EBV-encoded EBNA3,68 and the inﬂuenzaAmatrix peptide
M1.69,70 However, when the TCR-sequences of TT-speciﬁc
T-cell clones of recipients (group III) were compared with those
of their donors, striking differences were observed in the TCR
gene segment usage and in the amino acid composition of the
TCR CDR3-region (Table 5). Although we cannot exclude that
these antigen-reactive T cells recognize different TT-epitopes,
these observations suggest that theTT-reactiveTcells present in
the recipient at 52 weeks after allo-BMT originate from
Fig 4. Proliferative responses of T-cell lines at 1 year after allo-BMT. 3H-thymidine incorporation assays of TT-specific T-cell lines after
stimulation with PHA, TT, or culture medium as negative control. Depicted on the y-axis is the SI: SI 5 3H thymidine incorporation of T-cell lines 1
APC1 TT/3H thymidine incorporation of T-cell lines 1 APC only. Shown are the results of 2 recipients of transplantation groups I (UPN 272 and
279) and III (UPN 275 and 285) and of 1 recipient of group II (UPN 301) and of their corresponding BM donors.
Fig 5. Determination of the restriction element of T-cell clones
upon inhibition of TT-specific proliferation with specific MoAbs.
Percentage blocking of TT-specific proliferation was determined
using anti-CD4 (RIV6), anti-MHC class I (W6/32), anti-MHC class II
(PdV5.2), and anti-HLA DR (B8.11.2) MoAbs. In each experiment,
autologous B-cell lines were used as APC. Percentage inhibition was
calculated as follows:100 2 (SI TT1MoAb/SI TT alone 3 100%).
Shown are the results of 2 representative T-cell clones ([j] UPN275 cl
40 and [Y] UPN 285 cl 2).
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recipient either in the thymus27-29 or extrathymically.30,31 This is
supported by the observation that all T cells in UPN 275 and
UPN 285 were of donor origin at 52 weeks post-BMT.
Furthermore, in both children, the absolute number of naive
CD41CD45RA1 T cells, which are most probably recent
thymic emigrants, increased in time (Table 3). Previous studies
in SCID patients have shown differential MHC restriction
patterns after HLA haploidentical BMT, which also points to a
thymic-dependent pathway for the regeneration of CD41Tcells
after transplantation.37,71
The mechanisms involved in the complete restoration of the
T-cell immune repertoire after allo-BMT in humans are poorly
understood. Peripheral expansion of mature graft-derived T
cells4,22 as well as selection of precursor T cells22,29 in the
thymus or extrathymically are thought to play an important role
in this process. The T-cell selection pathway, which may be
affected by aging,72 is probably more important for the complete
recovery of CD41 than for CD81 T cells, because the latter
population recovers earlier after BMT (Table 3) and even in
thymectomized pediatric recipients50 and in adults.7,41 The
recovery of CD41 and CD81 T-cell numbers, the increase of
overall TCR-diversity, the restoration of an antigen-speciﬁc
proliferative response, and the differences inTCR gene segment
usage of TT-speciﬁc T cells that were observed in our pediatric
recipients within the ﬁrst year after allo-BMT most likely point
to complete T-cell immune reconstitution via selection of
precursor T cells in the thymus and possibly also at extrathymic
sites.
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